Antiproliferative activity of levobupivacaine and aminoimidazole carboxamide ribonucleotide on human cancer cells of variable bioenergetic profile

Mitochondrion

Volumn 12, Issue 1, 2012, Pages 100-109

  Jose, Caroline ^a,b,c   Bellance, Nadège ^a,b,c   Chatelain, Etienne Hébert ^a,b,c   Benard, Giovanni ^a,b,c   Nouette Gaulain, Karine ^a,b,c   Rossignol, Rodrigue ^a,b,c  

^a Laboratoire Maladies Rares Génétique et Métabolisme Bordeaux University   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

^c BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

AICAR; Bezafibrate; Cancer; Levobupivacaine; Lidocaine; Local anesthesia; Mepivacaine; Oxidative phosphorylation; Pioglitazone; Ropivacaine; Rosiglitazone

Indexed keywords

5 AMINO 4 IMIDAZOLECARBOXAMIDE RIBOSIDE; ADENOSINE TRIPHOSPHATE; BEZAFIBRATE; BUPIVACAINE; DOXORUBICIN; LEVOBUPIVACAINE; LIDOCAINE; MEPIVACAINE; PIOGLITAZONE; RESVERATROL; ROPIVACAINE; ROSIGLITAZONE;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL PROLIFERATION; CELL RESPIRATION; CELL TYPE; CELL VIABILITY; CONTROLLED STUDY; DRUG POTENCY; FIBROBLAST; GLYCOLYSIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ADENOSINE TRIPHOSPHATE; ADOLESCENT; ADULT; AGED; AMINOIMIDAZOLE CARBOXAMIDE; ANTINEOPLASTIC AGENTS; BUPIVACAINE; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; ENERGY METABOLISM; FEMALE; HUMANS; MALE; RIBONUCLEOTIDES;

EID: 84856557998     PISSN: 15677249     EISSN: 18728278     Source Type: Journal    
DOI: 10.1016/j.mito.2011.03.010     Document Type: Article

References (49)

1. Bellance N., Lestienne P., Rossignol R. Mitochondria: from bioenergetics to the metabolic regulation of carcinogenesis. Front. Biosci. 2009, 14:4015-4034.
2. Benard G., Faustin B., Passerieux E., Galinier A., Rocher C., Bellance N., Delage J.P., Casteilla L., Letellier T., Rossignol R. Physiological diversity of mitochondrial oxidative phosphorylation. Am. J. Physiol. Cell Physiol. 2006, 291:C1172-C1182.
3. Benbrik E., Chariot P., Bonavaud S., Ammi-Said M., Frisdal E., Rey C., Gherardi R., Barlovatz-Meimon G. Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cells. J. Neurol. Sci. 1997, 149:19-25.
4. Bogacka I., Xie H., Bray G.A., Smith S.R. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 2005, 54:1392-1399.
5. Borenfreund E., Puerner J.A. Toxicity determined in vitro by morphological alterations and neutral red absorption. Toxicol. Lett. 1985, 24:119-124.
6. Canto C., Gerhart-Hines Z., Feige J.N., Lagouge M., Noriega L., Milne J.C., Elliott P.J., Puigserver P., Auwerx J. AMPK regulates energy expenditure by modulating NAD+metabolism and SIRT1 activity. Nature 2009, 458:1056-1060.
7. Chance B., Williams G.R. The respiratory chain and oxidative phophorylation. Adv. Enzymol. 1956, 17:65-134.
8. Dixon R., Gourzis J., McDermott D., Fujitaki J., Dewland P., Gruber H. AICA-riboside: safety, tolerance, and pharmacokinetics of a novel adenosine-regulating agent. J. Clin. Pharmacol. 1991, 31:342-347.
9. D'Souza G.G., Wagle M.A., Saxena V., Shah A. Approaches for Targeting Mitochondria in Cancer Therapy 2010, Biochim Biophys Acta.
10. Dykens J.A., Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov. Today 2007, 12:777-785.
11. Folkers K., Langsjoen P., Willis R., Richardson P., Xia L.J., Ye C.Q., Tamagawa H. Lovastatin decreases coenzyme Q levels in humans. Proc Natl Acad Sci USA 1990, 87:8931-8934.
12. Fulda S., Galluzzi L., Kroemer G. Targeting mitochondria for cancer therapy. Nat. Rev. Drug Discov. 2010, 9:447-464.
13. Galbes O., Bourret A., Nouette-Gaulain K., Pillard F., Matecki S., Py G., Mercier J., Capdevila X., Philips A. N-acetylcysteine protects against bupivacaine-induced myotoxicity caused by oxidative and sarcoplasmic reticulum stress in human skeletal myotubes. Anesthesiology 2010, 113:560-569.
14. Gstraunthaler G., Seppi T., Pfaller W. Impact of culture conditions, culture media volumes, and glucose content on metabolic properties of renal epithelial cell cultures. Are renal cells in tissue culture hypoxic?. Cell. Physiol. Biochem. 1999, 9:150-172.
15. Guo D., Hildebrandt I.J., Prins R.M., Soto H., Mazzotta M.M., Dang J., Czernin J., Shyy J.Y., Watson A.D., Phelps M., Radu C.G., Cloughesy T.F., Mischel P.S. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci USA 2009, 106:12932-12937.
16. Hutter E., Renner K., Pfister G., Stockl P., Jansen-Durr P., Gnaiger E. Senescence-associated changes in respiration and oxidative phosphorylation in primary human fibroblasts. Biochem. J. 2004, 380:919-928.
17. Jose C., Bellance N., Rossignol R. Choosing between Glycolysis and Oxidative Phosphorylation: a Tumor's Dilemma? 2010, Biochim Biophys Acta.
18. Jose C., Hebert-Chatelain E., Bellance N., Larendra A., Su M., Nouette-Gaulain K., Rossignol R. AICAR Inhibits Cancer Cell Growth and Triggers Cell-type Distinct Effects on OXPHOS Biogenesis, Oxidative Stress and Akt Activation 2010, Biochim Biophys Acta.
19. Jung J.E., Lee J., Ha J., Kim S.S., Cho Y.H., Baik H.H., Kang I. 5-Aminoimidazole-4-carboxamide-ribonucleoside enhances oxidative stress-induced apoptosis through activation of nuclear factor-kappaB in mouse neuro 2a neuroblastoma cells. Neurosci. Lett. 2004, 354:197-200.
20. Kallinowski F., Schlenger K.H., Kloes M., Stohrer M., Vaupel P. Tumor blood flow: the principal modulator of oxidative and glycolytic metabolism, and of the metabolic micromilieu of human tumor xenografts in vivo. Int. J. Cancer 1989, 44:266-272.
21. Kim J., Woo A.J., Chu J., Snow J.W., Fujiwara Y., Kim C.G., Cantor A.B., Orkin S.H. A Myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell 2010, 143:313-324.
22. Lagouge M., Argmann C., Gerhart-Hines Z., Meziane H., Lerin C., Daussin F., Messadeq N., Milne J., Lambert P., Elliott P., Geny B., Laakso M., Puigserver P., Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006, 127:1109-1122.
23. Lee J.O., Lee S.K., Jung J.H., Kim J.H., You G.Y., Kim S.J., Park S.H., Uhm K.O., Kim H.S. Metformin induces Rab4 through AMPK and modulates GLUT4 translocation in skeletal muscle cells. J. Cell. Physiol. 2010.
24. Nouette-Gaulain K., Forestier F., Malgat M., Marthan R., Mazat J.P., Sztark F. Effects of bupivacaine on mitochondrial energy metabolism in heart of rats following exposure to chronic hypoxia. Anesthesiology 2002, 97:1507-1511.
25. Nouette-Gaulain K., Sirvent P., Canal-Raffin M., Morau D., Malgat M., Molimard M., Mercier J., Lacampagne A., Sztark F., Capdevila X. Effects of intermittent femoral nerve injections of bupivacaine, levobupivacaine, and ropivacaine on mitochondrial energy metabolism and intracellular calcium homeostasis in rat psoas muscle. Anesthesiology 2007, 106:1026-1034.
26. Nouette-Gaulain K., Bellance N., Prevost B., Passerieux E., Pertuiset C., Galbes O., Smolkova K., Masson F., Miraux S., Delage J.P., Letellier T., Rossignol R., Capdevila X., Sztark F. Erythropoietin protects against local anesthetic myotoxicity during continuous regional analgesia. Anesthesiology 2009, 110:648-659.
27. Nouette-Gaulain K., Dadure C., Morau D., Pertuiset C., Galbes O., Hayot M., Mercier J., Sztark F., Rossignol R., Capdevila X. Age-dependent bupivacaine-induced muscle toxicity during a continuous peripheral nerve block in rat. Anesthesiology 2009, 111:1120-1127.
28. Nouette-Gaulain K., Dadure C., Morau D., Pertuiset C., Galbes O., Hayot M., Mercier J., Sztark F., Rossignol R., Capdevila X. Age-dependent bupivacaine-induced muscle toxicity during continuous peripheral nerve block in rats. Anesthesiology 2009, 111:1120-1127.
29. Nouette-Gaulain K., Bringuier S., Canal-Raffin M., Bernard N., Lopez S., Dadure C., Masson F., Mercier J., Sztark F., Rossignol R., Capdevila X. Time course of mitochondrial metabolism alterations to repeated injections of bupivacaine in rat muscle. Can. J. Anaesth. 2010, 57:836-842.
30. Nouette-Gaulain K., Jose C., Capdevila X., Rossignol R. From Analgesia to Myopathy: when Local Anesthetics Impair the Mitochondrion 2010, Int J Biochem Cell Biol.
31. Rattan R., Giri S., Singh A.K., Singh I. 5-Aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase. J. Biol. Chem. 2005, 280:39582-39593.
32. Schonfeld P., Sztark F., Slimani M., Dabadie P., Mazat J.P. Is bupivacaine a decoupler, a protonophore or a proton-leak-inducer?. FEBS Lett. 1992, 304:273-276.
33. Sengupta T.K., Leclerc G.M., Hsieh-Kinser T.T., Leclerc G.J., Singh I., Barredo J.C. Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells: implication for targeted therapy. Mol. Cancer 2007, 6:46.
34. Smolkova K., Bellance N., Scandurra F., Genot E., Gnaiger E., Plecita-Hlavata L., Jezek P., Rossignol R. Mitochondrial bioenergetic adaptations of breast cancer cells to aglycemia and hypoxia. J. Bioenerg. Biomembr. 2010, 42:55-67.
35. Su R.Y., Chao Y., Chen T.Y., Huang D.Y., Lin W.W. 5-Aminoimidazole-4-carboxamide riboside sensitizes TRAIL- and TNF{alpha}-induced cytotoxicity in colon cancer cells through AMP-activated protein kinase signaling. Mol. Cancer Ther. 2007, 6:1562-1571.
36. Sun X., Garlid K.D. On the mechanism by which bupivacaine conducts protons across the membranes of mitochondria and liposomes. J. Biol. Chem. 1992, 267:19147-19154.
37. Suwa M., Egashira T., Nakano H., Sasaki H., Kumagai S. Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. J. Appl. Physiol. 2006, 101:1685-1692.
38. Sztark F., Malgat M., Dabadie P., Mazat J.P. Comparison of the effects of bupivacaine and ropivacaine on heart cell mitochondrial bioenergetics. Anesthesiology 1998, 88:1340-1349.
39. Sztark F., Nouette-Gaulain K., Malgat M., Dabadie P., Mazat J.P. Absence of stereospecific effects of bupivacaine isomers on heart mitochondrial bioenergetics. Anesthesiology 2000, 93:456-462.
40. Tenenbaum A., Boyko V., Fisman E.Z., Goldenberg I., Adler Y., Feinberg M.S., Motro M., Tanne D., Shemesh J., Schwammenthal E., Behar S. Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?. Cardiovasc. Diabetol. 2008, 7:18.
41. Terada H., Shima O., Yoshida K., Shinohara Y. Effects of the local anesthetic bupivacaine on oxidative phosphorylation in mitochondria. Change from decoupling to uncoupling by formation of a leakage type ion pathway specific for H+in cooperation with hydrophobic anions. J. Biol. Chem. 1990, 265:7837-7842.
42. van Ginkel P.R., Sareen D., Subramanian L., Walker Q., Darjatmoko S.R., Lindstrom M.J., Kulkarni A., Albert D.M., Polans A.S. Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin. Cancer Res. 2007, 13:5162-5169.
43. Vaupel P., Hockel M. Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance. Int. J. Oncol. 2000, 17:869-879.
44. Wei S., Kulp S.K., Chen C.S. Energy restriction as an antitumor target of thiazolidinediones. J. Biol. Chem. 2010, 285:9780-9791.
45. Wenz T., Diaz F., Spiegelman B.M., Moraes C.T. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab. 2008, 8:249-256.
46. Wilson-Fritch L., Burkart A., Bell G., Mendelson K., Leszyk J., Nicoloro S., Czech M., Corvera S. Mitochondrial biogenesis and remodeling during adipogenesis and in response to the insulin sensitizer rosiglitazone. Mol. Cell. Biol. 2003, 23:1085-1094.
47. Woodard J., Platanias L.C. AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem. Biophys. Res. Commun. 2010, 398:135-139.
48. Yu S.Y., Chan D.W., Liu V.W., Ngan H.Y. Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-activated protein kinase. Tumour Biol. 2009, 30:80-85.
49. Zu X.L., Guppy M. Cancer metabolism: facts, fantasy, and fiction. Biochem. Biophys. Res. Commun. 2004, 313:459-465.